Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-04-13 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2011-04-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release about clinical trial results for the drug Gilenya, including efficacy and safety data, and information about the company's operations and contact details. There are no detailed financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management report. It is a regulatory filing used to disclose material information to the SEC and investors. Given the nature of the document as a Form 6-K with a press release and no substantive financial data, it fits best under Regulatory Filings (RNS). The document length is over 11,000 characters, so it is not a brief announcement but a full regulatory filing. Therefore, the classification is RNS with high confidence.
2011-04-12 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the discontinuation of a clinical trial for Tasigna in a specific indication. It contains no financial statements or detailed financial data, but rather a corporate announcement about clinical trial status and forward-looking statements. The document length is 8684 characters, which is relatively short and consistent with a press release or regulatory announcement rather than a full financial report. There is no indication that this is an annual or interim report, audit report, earnings release, or other financial filing. The document is primarily a regulatory announcement informing the market about clinical trial discontinuation and related information. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-04-12 English
AMENDMENT NO. 4 TO SCHEDULE 13E-3
Regulatory Filings Classification · 95% confidence The document is titled 'Amendment No. 4 to Schedule 13E-3' and is a filing with the SEC under Rule 13e-3 of the Securities Exchange Act of 1934. It reports the results of a transaction involving a merger between Novartis AG and Alcon, Inc. The document includes details about shareholder approvals, merger completion dates, and the delisting of Alcon shares from the NYSE. The Schedule 13E-3 is a transaction statement related to going-private transactions or similar corporate actions. This document is not a full annual or quarterly report, audit report, earnings release, or other financial report. It is a regulatory filing specifically reporting the results of a transaction and related corporate actions. Therefore, it fits best under the category 'Regulatory Filings' (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2011-04-11 English
Regulatory Filings 2011
Regulatory Filings
2011-04-11 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing an amendment to a US FDA application for a drug indication. It does not contain financial statements or detailed financial analysis. The document is approximately 9309 characters, which is relatively short and primarily serves as a regulatory announcement about a drug application update and related regulatory process. There is no indication of it being an annual or quarterly report, audit report, earnings release, or any other detailed financial or governance report. It is a regulatory filing providing material information to investors and the SEC but not a full report itself. Therefore, it fits best under Regulatory Filings (RNS).
2011-04-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.